Cangene Corp. received approval from the Ontario Superior Court of Justice for the previously announced acquisition of Cangene by Emergent BioSolutions, Inc. Under the court-approved Plan of Arrangement, Cangene shareholders will receive $3.24 per share in cash, for an aggregate purchase price of $222 million.
 
The transaction, subject to additional customary closing conditions, is expected to close in February 2014.